MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 8, 2006; DOI: 10.1124/mol.106.025619


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.025619v1
70/5/1488    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Belousova, N.
Right arrow Articles by Alvarez, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belousova, N.
Right arrow Articles by Alvarez, R. D.


Received for publication May 4, 2006.
Revised August 7, 2006.
Accepted for publication August 8, 2006.

Circumventing recombination events encountered with production of a clinical-grade adenoviral vector with a double-expression cassette

Natalya Belousova 1, Raymond Harris 2, Kurt Zinn 3, Mary Ann Rhodes-Selser 2, Alexander Kotov 4, Olga Kotova 3, Minghui Wang 3, Rosemarie Aurigemma 5, Zeng B. Zhu 3, David T. Curiel 3*, Ronald D. Alvarez 3

1 The University of Texas, M. D. Anderson Cancer Center 2 SAIC-Frederick, Inc., National Cancer Institute at Frederick 3 The University of Alabama at Birmingham 4 VIRxSYS Corporation 5 NCI-Frederick

* Address correspondence to: E-mail: curiel{at}uab.edu

Abstract

Delivery of multiple exogenous genes into target cells is important for a broad range of gene therapy applications, including combined therapeutic gene expression and noninvasive imaging. Previous studies (1) described the adenoviral vector RGDTKSSTR with a double-expression cassette that encodes herpes simplex virus thymidine kinase (HSVtk) for molecular chemotherapy and human somatostatin receptor subtype-2 (hSSTR2) for indirect imaging. In this vector, both genes are inserted in place of the E1 region of the adenoviral genome and expressed independently from two cytomegalovirus (CMV) promoters. During production of clinical-grade RGDTKSSTR, we found that the CMV promoters and SV40 polyA regions located in both expression cassettes provoked homologous recombination and deletion of one of the cassettes. To resolve this problem, we designed a strategy for substituting the duplicate promoters and polyA regions. We placed the hSSTR2 gene in the new Ad5.SSTR/TK.RGD vector under the control of a CMV promoter with a bovine growth hormone (BGH) polyA region, whereas the SV40 promoter, enhancer, and polyA signal controlled HSVtk expression. This use of different regulatory sequences allowed independent expression of both transgenes from a single adenoviral vector and circumvented the recombination problem. Reconstruction of the vector with a double-expression cassette enables its use in human clinical trials.


Key words: Somatostatin, Antisense, Knockout, Overexpression, Ribozymes, RNA/siRNA


This article has been cited by other articles:


Home page
JNMHome page
D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn
Tumor Receptor Imaging
J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S.
[Abstract] [Full Text] [PDF]


Home page
J. Gen. Virol.Home page
R. Vogels, D. Zuijdgeest, M. van Meerendonk, A. Companjen, G. Gillissen, J. Sijtsma, I. Melis, L. Holterman, K. Radosevic, J. Goudsmit, et al.
High-level expression from two independent expression cassettes in replication-incompetent adenovirus type 35 vector
J. Gen. Virol., November 1, 2007; 88(11): 2915 - 2924.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics